A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major

Pediatric Blood and Cancer

Volumn 58, Issue 6, 2012, Pages 910-915

  Elalfy, Mohsen S ^a   Massoud, Walid ^b   Elsherif, Nayera H ^a   Labib, Jonair H ^a   Elalfy, Omar M ^a   Elaasar, Safaa ^c   von Mackensen, Sylvia ^d  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AMERICAN UNIVERSITY IN CAIRO   (Egypt)

^c Ain Shams University   (Egypt)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adherence; ICT Sat; Iron chelators; Patient rated outcome; Questionnaire; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; IRON CHELATING AGENT;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ASSESSMENT; EGYPT; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INJECTION SITE REACTION; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT SATISFACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; PSYCHOMETRY; QUESTIONNAIRE; RASH; SCHOOL CHILD; SIDE EFFECT; THALASSEMIA MAJOR; THERAPY EFFECT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; EGYPT; FEMALE; HUMANS; INFANT; IRON CHELATING AGENTS; MALE; PATIENT SATISFACTION; PSYCHOMETRICS; QUESTIONNAIRES; YOUNG ADULT;

EID: 84858629638     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23413     Document Type: Article

References (38)

1. Galanello R, Origa R. Beta-thalassemia. Orphaned J Rare Dis 2010; 5: 11-25.
2. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: Quantitative disorders of hemoglobin synthesis. In: Wintrobe's Clinical Hematology (Volume 42), 11th edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p 1319-1365.
3. Abetz L, Baladi JF, Jones P, et al. The impact of iron overload and its treatment on quality of life: Results from a literature review. Health Qual Life Outcomes 2006; 4: 73.
4. Wood JC, Noetzl L, Hyderi A, et al. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci 2010; 1202: 123-128.
5. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-1236.
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
7. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
8. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3.
9. ElAlfy M, Sari TT, Lee CL, et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010; 32: 601-605.
10. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2005; 107: 3738-3744.
11. Taher A, Sheikh-Taha M, Sharara A, et al. Safety and effectiveness of 100mg/kg/day deferiprone in patients with thalassemia major: A two-year study. Acta Haematol 2005; 114: 146-149.
12. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-520.
13. Piga A, Roggero S, Vinciguerra T, et al. Deferiprone: New insight. Ann N Y Acad Sci 2005; 1054: 169-174.
14. Piga A, Roggero S, Salussolia I, et al. Deferiprone. Ann N Y Acad Sci 2010; 1202: 75-78.
15. Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009; 122: 165-173.
16. Yew CT, Talaulikar GS, Falk MC, et al. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology (Carlton) 2010; 15: 377.
17. Grangé S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010; 25: 2376-2378.
18. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother 2008; 9: 2391-2402.
19. Sánchez-González PD, López-Hernandez FJ, Morales AI, et al. Effects of deferasirox on renal function and renal epithelial cell death. Toxicol Lett 2011; 203: 154-161.
20. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study. Eur J Haematol 2009; 82: 458-465.
21. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115: 2364-2371.
22. Cappellini MD, Porter J, El-Beshlawy A, et al. EPIC Study Investigators: Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-566.
23. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in â-thalassemia major patients with cardiac iron overload. Haematologica 2011; 96: 48-54.
24. Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: Cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011; 96: 41-47.
25. Weaver M, Patrick DL, Markson LE, et al. Issues in the management of satisfaction with treatment. A J Manag Care 1997; 3: 579-594.
26. Albrecht G, Hoogstraten J. Satisfaction as a determinant of compliance. Community Dent Oral Epidemiol 1998; 26: 139-146.
27. Taher A, Al Jefri, Elalfy A, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol 2010; 123: 220-225.
28. Larsen DE, Rootman I. Physician role performance patient satisfaction. Soc Sci Med 1976; 10: 29-32.
29. Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health 2009; 12: 109-117.
30. Frick U, Gutzwiller FS, Maggiorini M, et al. A questionnaire on treatment satisfaction and disease specific knowledge among patients with acute coronary syndrome. II: Insights for patient education and quality improvement. Patient Educ Couns 2011; [Epub ahead of print].
31. Atkinson MJ, Kumar R, Cappelleri JC, et al. Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy Consumers. Value Health 2005; 8: S9-S24.
32. Staquet NJ, Hays RD, Fayers PN. Quality of life assessments in clinical trials: Methods and practice. Oxford: Oxford University Press; 1998.
33. Albright JJ, Hun MP. Confirmatory Factor Analysis Using Amos, LISREL, Mplus, SAS/STAT CALIS. Working Paper. The University Information Technology Services (UITS) Center for Statistical and Mathematical Computing 2009, Indiana University.
34. Nunnally JC. Psychometric theory, 2nd edition. New York: McGraw Hill; 1978.
35. Luangasanatip N, Chaiyakunapruk N, Upakdee N, et al. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: A cost-effectiveness study. Clin Drug Investig 2011; 31: 493-505.
36. Dahlui M, Hishamshah MI, Rahman AJA, et al. Quality of life in transfusion dependent thalassaemia patients on desferrioxamine treatment. Singapore Med J 2009; 50: 794-799.
37. Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy (ICT) in the United States. Transfusion 2007; 47: 1820-1829.
38. Atkin K, Ahmad WIU. Family care giving and chronic illness: How parents cope with a child with sickle cell disorder or thalassaemia. Health Soc Care Community 2000; 8: 57-69.